NEW YORK, July 09, 2024 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. (“Accolade” or “the Company”) (NASDAQ: ACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ACCD.
Investigation Details
On June 27, 2024, Accolade reported a quarterly loss of $0.35 per share. Following its earnings release, Accolade stock dropped by more than 27% in after-hours trading.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Accolade securities, you can assist this investigation by visiting the firm’s site: bgandg.com/ACCD. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
- Students from University Inkjet Program-Member Schools Visit Canon Customers For First-Hand Experience in the Printing Industry - April 30, 2025
- MissionSquare Retirement names Tom McAndrews as Chief Legal Officer - April 30, 2025
- WisdomTree Multi Asset Issuer Public Limited Company(a public company incorporated with limited liability in Ireland) Collateralised ETP Securities ProgrammeReport and Financial Statements for year ended 31 December 2024 - April 30, 2025